Navigation Links
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Date:2/13/2013

ATLANTA, Feb. 13, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2013 of $0.025 per share of common stock outstanding.  The quarterly cash dividend of $0.025 per share will be paid on March 21, 2013 to all common stockholders of record as of March 14, 2013.  The ex-dividend date for the quarterly dividend is March 12, 2013. 

CryoLife anticipates paying quarterly dividends in March, June, September, and December of each year.  Based on the number of shares currently outstanding, the Company expects to pay a total annual dividend of approximately $2.7 million.  These statements represent management's current beliefs and expectations and are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to risks and uncertainties that could cause future events to deviate from current expectations, including without limitation that the declaration of future dividends and the establishment of the per share amount, record dates, and payment dates for future dividends are subject to final determination by the Company's Board of Directors, and will be dependent upon future earnings, cash flows, financial requirements, the Board's evaluation of competing uses for available cash, and other factors.

About CryoLifeFounded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europe, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of congenital heart defects.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical.

For additional information about CryoLife, visit CryoLife's website, www.cryolife.com.Contacts:CryoLife The Ruth GroupD. Ashley Lee

Nick Laudico / Zack KubowExecutive Vice President, Chief Financial Officer

646-536-7030 / 7020and Chief Operating Officer

nlaudico@theruthgroup.com Phone: 770-419-3355

zkubow@theruthgroup.com


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
2. CryoLife Receives Expanded Indication for BioFoam in Europe
3. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
4. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
5. CryoLife Announces Initiation of Quarterly Cash Dividend
6. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
7. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
8. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
9. CryoLife Completes Acquisition of Hemosphere
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Xenon Announces Appointment of EVP, Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... grow in 2017-2023. Various reasons for growth of the ... higher incidences of chronic diseases, high recovery cost of ... services. Medical lifting sling refers to an assistive ... mobility. These slings connect to the lift and hold ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... diagnostics includes products and tests that are used ... grass, weed, peanuts, milk, or drugs etc. in ... developed by the immune system. The report on ... future prospects of the market. The report consists ...
Breaking Medicine Technology:
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... ... , ... DrugDev again demonstrated its dedication to reducing the administrative ... adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. , ... the Atlantic with a mechanism to comply with EU data protection requirements when transferring ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and ... comprehensive mental health systems reform legislation in more than fifty years. We applaud ... commitment of our elected officials to improving mental health services and supports in ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
Breaking Medicine News(10 mins):